Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

References

• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• van Velthoven CT, Kavelaars A, van Bel F, et al. Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res. 2010 Nov;68(5):419–422.
   PubMed Web of Science ®Google Scholar
• Sun J, Wei ZZ, Gu X, et al. Intranasal delivery of hypoxia-preconditioned bone marrow-derived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice. Exp Neurol. 2015;272:78–87.
   PubMed Web of Science ®Google Scholar
• Lunn JS, Sakowski SA, Hur J, et al. Stem cell technology for neurodegenerative diseases. Ann Neurol. 2011 Sep;70(3):353–361.
   PubMed Web of Science ®Google Scholar
• Dey M, Yu D, Kanojia D, et al. Intranasal oncolytic virotherapy with CXCR4-enhanced stem cells extends survival in mouse model of glioma. Stem Cell Reports. 2016 Sep 13;7(3):471–482.
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127(2):481–496.
   PubMed Web of Science ®Google Scholar
• Dhanda DS, Ii Wh F, Leopold D, et al. Approaches for drug deposition in the human olfactory epithelium. Drug Delivery Technol. 2005;5:64–72.
   Google Scholar
• Schrepfer S, Deuse T, Reichenspurner H, et al. Stem cell transplantation: the lung barrier. Transplant Proc. 2007 Mar;39(2):573–576.
   PubMed Web of Science ®Google Scholar
• Gao J, Dennis JE, Muzic RF, et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169(1):12–20.
   PubMed Web of Science ®Google Scholar
• Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicologic Pathology. 2006;34(3):252–269.
   PubMed Web of Science ®Google Scholar
• Treuting PM, Dintzis SM, Montine KS. Comparative anatomy and histology a mouse and human atlas introduction. In: Frevert CW, Liggitt D, editors. Comparative anatomy and histology: a mouse and human atlas. Cambridge, (MA): Academic Press; 2011. p. 1–6.
   Google Scholar
• Adams DR. Olfactory and non-olfactory epithelia in the nasal cavity of the mouse, Peromyscus. Am J Anat. 1972 Jan;133(1):37–49.
   PubMedGoogle Scholar
• Balyasnikova IV, Prasol MS, Ferguson SD, et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther. 2014 Jan;22(1):140–148.
   PubMed Web of Science ®Google Scholar
• Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther. 2004 May;309(2):469–475.
   PubMed Web of Science ®Google Scholar
• Danielyan L, Beer-Hammer S, Stolzing A, et al. Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant. 2014;23(Suppl 1):S123–39.
   PubMedGoogle Scholar
• Danielyan L, Schafer R, von Ameln-Mayerhofer A, et al. Intranasal delivery of cells to the brain. Eur J Cell Biol. 2009 Jun;88(6):315–324.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010 Apr;99(4):1654–1673.
   PubMed Web of Science ®Google Scholar
• Lochhead JJ, Wolak DJ, Pizzo ME, et al. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab. 2015 Mar;35(3):371–381.
   PubMed Web of Science ®Google Scholar
• Reitz M, Demestre M, Sedlacik J, et al. Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl Med. 2012 Dec;1(12):866–873.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther. 2009 Jan;328(1):312–320.
   PubMed Web of Science ®Google Scholar
• Ross TM, Zuckermann RN, Reinhard C, et al. Intranasal administration delivers peptoids to the rat central nervous system. Neurosci Lett. 2008 Jul 4;439(1):30–33.
   PubMed Web of Science ®Google Scholar
• Thorne RG, Hanson LR, Ross TM, et al. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience. 2008 Mar 27;152(3):785–797.
   PubMed Web of Science ®Google Scholar
• Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846–12851.
   PubMed Web of Science ®Google Scholar
• Bexell D, Gunnarsson S, Tormin A, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther. 2009 Jan;17(1):183–190.
   PubMed Web of Science ®Google Scholar
• Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005 Apr 15;65(8):3307–3318.
   PubMed Web of Science ®Google Scholar
• Zhao D, Najbauer J, Garcia E, et al. Neural stem cell tropism to glioma: critical role of tumor hypoxia. Molecular Cancer Res. 2008 Dec;6(12):1819–1829.
   PubMed Web of Science ®Google Scholar
• Schmidt NO, Przylecki W, Yang W, et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia (New York, NY). 2005 Jun;7(6):623–629.
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004 Aug;10(8):858–864.
   PubMed Web of Science ®Google Scholar
• Xu G, Guo Y, Seng Z, et al. Bone marrow-derived mesenchymal stem cells co-expressing interleukin-18 and interferon-beta exhibit potent antitumor effect against intracranial glioma in rats. Oncol Rep. 2015 Oct;34(4):1915–1922.
   PubMed Web of Science ®Google Scholar
• Birnbaum T, Roider J, Schankin CJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol. 2007 Jul;83(3):241–247.
   PubMed Web of Science ®Google Scholar
• Merzaban JS, Imitola J, Starossom SC, et al. Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis. Glycobiology. 2015 Dec;25(12):1392–1409.
   PubMed Web of Science ®Google Scholar
• Ma JC, Cheng P, Hu Y, et al. Integrin alpha4 is involved in the regulation of glioma-induced motility of bone marrow mesenchymal stem cells. Oncol Rep. 2015 Aug;34(2):779–786.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim JM, Cho SY, et al. TIMP-1 modulates chemotaxis of human neural stem cells through CD63 and integrin signalling. Biochem J. 2014 May 1;459(3):565–576.
   PubMed Web of Science ®Google Scholar
• Ziu M, Schmidt NO, Cargioli TG, et al. Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol. 2006 Sep;79(2):125–133.
   PubMed Web of Science ®Google Scholar
• Xu F, Shi J, Yu B, et al. Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncol Rep. 2010 Jun;23(6):1561–1567.
   PubMed Web of Science ®Google Scholar
• McGrath KE, Koniski AD, Maltby KM, et al. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Developmental Biology. 1999 Sep 15;213(2):442–456.
   PubMed Web of Science ®Google Scholar
• Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies. Gene Ther. 2008 May;15(10):716–729.
   PubMed Web of Science ®Google Scholar
• Ahmed AU, Rolle CE, Tyler MA, et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther. 2010 Oct;18(10):1846–1856.
   PubMed Web of Science ®Google Scholar
• Ozduman K, Wollmann G, Piepmeier JM, et al. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci. 2008 Feb 20;28(8):1882–1893.
   PubMed Web of Science ®Google Scholar
• Kiprianova I, Thomas N, Ayache A, et al. Regression of glioma in rat models by intranasal application of parvovirus h-1. Clin Cancer Res. 2011 Aug 15;17(16):5333–5342.
   PubMed Web of Science ®Google Scholar
• Bongiorno EK, Garcia SA, Sauma S, et al. Type 1 immune mechanisms driven by the response to infection with attenuated rabies virus result in changes in the immune bias of the tumor microenvironment and necrosis of mouse GL261 brain tumors. J Immunol. 2017 Jun 01;198(11):4513–4523.
   PubMed Web of Science ®Google Scholar
• van Woensel M, Mathivet T, Wauthoz N, et al. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Sci Rep. 2017 Apr 27;7(1):1217.
   PubMedGoogle Scholar
• Aboody KS, Najbauer J, Metz MZ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med. 2013 May 8;5(184):184ra59.
   PubMed Web of Science ®Google Scholar
• Gutova M, Shahmanyan D, Oganesyan D, et al. Intranasal delivery of therapeutic neural stem cells to target intracerebral glioma. Enliven: J Stem Cells Regen Med. 2015 April 15;1(1):1–7.
   Google Scholar
• Uhl M, Weiler M, Wick W, et al. Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochem Biophys Res Commun. 2005 Mar 4;328(1):125–129.
   PubMed Web of Science ®Google Scholar
• Li S, Gao Y, Tokuyama T, et al. Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites. Cancer Lett. 2007 Jun 28;251(2):220–227.
   PubMed Web of Science ®Google Scholar
• Bak XY, Lam DH, Yang J, et al. Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma. Hum Gene Ther. 2011 Nov;22(11):1365–1377.
   PubMed Web of Science ®Google Scholar
• Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009 Feb;16(2):262–278.
   PubMed Web of Science ®Google Scholar
• Morshed RA, Gutova M, Juliano J, et al. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Ther. 2015 Jan;22(1):55–61.
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008 Mar;26(3):831–841.
   PubMed Web of Science ®Google Scholar
• Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009 Dec 1;69(23):8932–8940.
   PubMed Web of Science ®Google Scholar
• Duebgen M, Martinez-Quintanilla J, Tamura K, et al. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014 Jun;106(6):dju090.
   PubMedGoogle Scholar
• Ong HT, Federspiel MJ, Guo CM, et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol. 2013 Nov;59(5):999–1006.
   PubMed Web of Science ®Google Scholar
• Mader EK, Butler G, Dowdy SC, et al. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013;11:20.
   PubMed Web of Science ®Google Scholar
• Castleton A, Dey A, Beaton B, et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood. 2014 Feb 27;123(9):1327–1335.
   PubMed Web of Science ®Google Scholar
• Muroski ME, Morshed RA, Cheng Y, et al. Controlled payload release by magnetic field triggered neural stem cell destruction for malignant glioma treatment. PLoS One. 2016;11(1):e0145129.
   PubMed Web of Science ®Google Scholar
• Li L, Guan Y, Liu H, et al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano. 2011 Sep 27;5(9):7462–7470.
   PubMed Web of Science ®Google Scholar
• D’Ippolito G, Howard GA, Roos BA, et al. Isolation and characterization of marrow-isolated adult multilineage inducible (MIAMI) cells. Exp Hematol. 2006 Nov;34(11):1608–1610.
   PubMed Web of Science ®Google Scholar
• Roger M, Clavreul A, Huynh NT, et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm. 2012 Feb 14;423(1):63–68.
   PubMed Web of Science ®Google Scholar
• Lee DH, Ahn Y, Kim SU, et al. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res. 2009 Aug 1;15(15):4925–4934.
   PubMed Web of Science ®Google Scholar
• Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006 Dec 7;444(7120):761–765.
   PubMed Web of Science ®Google Scholar
• Li Q, Wijesekera O, Salas SJ, et al. Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival. Clin Cancer Res. 2014 May 1;20(9):2375–2387.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Bassoff N, Reinshagen C, et al. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Sci Rep. 2017 Jun 01;7(1):2602.
   PubMedGoogle Scholar
• Lopez-Ornelas A, Vergara P, Segovia J. Neural stem cells producing an inducible and soluble form of Gas1 target and inhibit intracranial glioma growth. Cytotherapy. 2014 Jul;16(7):1011–1023.
   PubMed Web of Science ®Google Scholar
• van Eekelen M, Sasportas LS, Kasmieh R, et al. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene. 2010 Jun 3;29(22):3185–3195.
   PubMed Web of Science ®Google Scholar
• Kim SK, Cargioli TG, Machluf M, et al. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res. 2005 Aug 15;11(16):5965–5970.
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Kabos P, Gutierrez MA, et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2002 Dec 15;62(24):7170–7174.
   PubMed Web of Science ®Google Scholar
• Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008 Dec 1;68(23):9614–9623.
   PubMed Web of Science ®Google Scholar
• Shah K, Bureau E, Kim DE, et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol. 2005 Jan;57(1):34–41.
   PubMed Web of Science ®Google Scholar
• Balyasnikova IV, Franco-Gou R, Mathis JM, et al. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Tissue Eng Regen Med. 2010 Jun;4(4):247–258.
   PubMed Web of Science ®Google Scholar
• Compte M, Cuesta AM, Sanchez-Martin D, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells. 2009 Mar;27(3):753–760.
   PubMed Web of Science ®Google Scholar
• Kanojia D, Balyasnikova IV, Morshed RA, et al. Neural Stem cells secreting anti-HER2 antibody improve survival in a preclinical model of HER2 overexpressing breast cancer brain metastases. Stem Cells. 2015 Oct;33(10):2985–2994.
   PubMed Web of Science ®Google Scholar
• Kim J, Hall RR, Lesniak MS, et al. Stem cell-based cell carrier for targeted oncolytic virotherapy: translational opportunity and open questions. Viruses. 2015 Dec;7(12):6200–6217.
   PubMed Web of Science ®Google Scholar
• Rome C, Gravier J, Morille M, et al. Near-infrared optical imaging of nucleic acid nanocarriers in vivo. Methods Mol Biol. 2013;948:49–65.
   PubMedGoogle Scholar
• David S, Passirani C, Carmoy N, et al. DNA nanocarriers for systemic administration: characterization and in vivo bioimaging in healthy mice. Mol Ther Nucleic Acids. 2013;2:e64.
   PubMedGoogle Scholar
• Fang C, Wang K, Stephen ZR, et al. Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces. 2015 Apr 1;7(12):6674–6682.
   PubMed Web of Science ®Google Scholar
• Goel S, Chen F, Hong H, et al. VEGF(1)(2, 1)-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl Mater Interfaces. 2014 Dec 10;6(23):21677–21685.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• Morille M, Montier T, Legras P, et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials. 2010 Jan;31(2):321–329.
   PubMed Web of Science ®Google Scholar
• Guerrero-Cazares H, Tzeng SY, Young NP, et al. Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano. 2014 May 27;8(5):5141–5153.
   PubMed Web of Science ®Google Scholar
• Huang FY, Lee TW, Chang CH, et al. Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model. Int J Nanomedicine. 2015;10:463–473.
   PubMed Web of Science ®Google Scholar
• Dreaden EC, Austin LA, Mackey MA, et al. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv. 2012 Apr;3(4):457–478.
   PubMedGoogle Scholar
• Li M, Deng H, Peng H, et al. Functional nanoparticles in targeting glioma diagnosis and therapies. J Nanosci Nanotechnol. 2014 Jan;14(1):415–432.
   PubMed Web of Science ®Google Scholar
• Ferreira E, Potier E, Logeart-Avramoglou D, et al. Optimization of a gene electrotransfer method for mesenchymal stem cell transfection. Gene Ther. 2008 Apr;15(7):537–544.
   PubMed Web of Science ®Google Scholar
• Musyanovych A, Schmitz-Wienke J, Mailander V, et al. Preparation of biodegradable polymer nanoparticles by miniemulsion technique and their cell interactions. Macromol Biosci. 2008 Feb 11;8(2):127–139.
   PubMed Web of Science ®Google Scholar
• Lorenz MR, Holzapfel V, Musyanovych A, et al. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials. 2006 May;27(14):2820–2828.
   PubMed Web of Science ®Google Scholar
• Huang X, Zhang F, Wang H, et al. Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery. Biomaterials. 2013 Feb;34(7):1772–1780.
   PubMed Web of Science ®Google Scholar
• Mangraviti A, Tzeng SY, Gullotti D, et al. Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival. Biomaterials. 2016;100:53–66.
   PubMed Web of Science ®Google Scholar
• Jackson C, Ruzevick J, Phallen J, et al. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol. 2011;2011:732413.
   PubMedGoogle Scholar
• Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res. 2011 Jul;31(7):545–552.
   PubMed Web of Science ®Google Scholar
• Williams RF, Sims TL, Tracey L, et al. Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells. Anticancer Res. 2010 Sep;30(9):3301–3308.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu H, Zeng X, et al. Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-beta in human glioma cells. Mol Neurobiol. 2013 Jun;47(3):1000–1010.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang G, Gao WW, et al. Induction of apoptosis in glioma cells and upregulation of Fas expression using the human interferon-beta gene. Asian Pac J Cancer Prev. 2012;13(6):2837–2840.
   PubMedGoogle Scholar
• Happold C, Roth P, Silginer M, et al. Interferon-beta induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol Cancer Ther. 2014 Apr;13(4):948–961.
   PubMed Web of Science ®Google Scholar
• Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol. 2010 Oct;21(Suppl 7):vii36–40.
   PubMedGoogle Scholar
• Morris JC, Waldmann TA. Antibody-based therapy of leukaemia. Expert Rev Mol Med. 2009;11:e29.
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Curr Opin Oncol. 2013 Nov;25(6):602–608.
   PubMed Web of Science ®Google Scholar
• Balyasnikova IV, Ferguson SD, Sengupta S, et al. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS One. 2010;5(3):e9750.
   PubMed Web of Science ®Google Scholar
• van den Berg MP, Romeijn SG, Verhoef JC, et al. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods. 2002 Apr 30;116(1):99–107.
   PubMed Web of Science ®Google Scholar
• Charlton ST, Davis SS, Illum L. Nasal administration of an angiotensin antagonist in the rat model: effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems. Int J Pharm. 2007 Jun 29;338(1–2):94–103.
   PubMed Web of Science ®Google Scholar
• Walter BA, Valera VA, Takahashi S, et al. Evidence of antibody production in the rat cervical lymph nodes after antigen administration into the cerebrospinal fluid. Arch Histol Cytol. 2006 Mar;69(1):37–47.
   PubMedGoogle Scholar
• Walter BA, Valera VA, Takahashi S, et al. The olfactory route for cerebrospinal fluid drainage into the peripheral lymphatic system. Neuropathol Appl Neurobiol. 2006 Aug;32(4):388–396.
   PubMed Web of Science ®Google Scholar
• Liu H, Ni Z, Chen Y, et al. Olfactory route for cerebrospinal fluid drainage into the cervical lymphatic system in a rabbit experimental model. Neural Regen Res. 2012 Apr 05;7(10):766–771.
   PubMed Web of Science ®Google Scholar
• Jogani VV, Shah PJ, Mishra P, et al. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):116–124.
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Mishra AK, et al. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. Journal of Drug Targeting. 2008 Dec;16(10):806–814.
   PubMed Web of Science ®Google Scholar
• Dufes C, Olivier JC, Gaillard F, et al. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm. 2003 Apr 14;255(1–2):87–97.
   PubMed Web of Science ®Google Scholar
• Chen SC, Eiting K, Cui K, et al. Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J Pharm Sci. 2006 Jun;95(6):1364–1371.
   PubMed Web of Science ®Google Scholar
• Raghavan U, Logan BM. New method for the effective instillation of nasal drops. J Laryngol Otol. 2000 Jun;114(6):456–459.
   PubMed Web of Science ®Google Scholar
• Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013 Feb;3(1):42–62.
   PubMed Web of Science ®Google Scholar
• van den Berg MP, Merkus P, Romeijn SG, et al. Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans. Journal of Drug Targeting. 2003 Jul;11(6):325–331.
   PubMed Web of Science ®Google Scholar
• van den Berg MP, Verhoef JC, Romeijn SG, et al. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm. 2004 Jul;58(1):131–135.
   PubMed Web of Science ®Google Scholar
• Danielyan L, Schafer R, von Ameln-Mayerhofer A, et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 2011 Feb;14(1):3–16.
   PubMed Web of Science ®Google Scholar
• Bossolasco P, Cova L, Levandis G, et al. Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson’s disease. Int J Nanomedicine. 2012;7:435–447.
   PubMed Web of Science ®Google Scholar
• Gutova M, Frank JA, D’Apuzzo M, et al. Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl Med. 2013 Oct;2(10):766–775.
   PubMed Web of Science ®Google Scholar
• Gu E, Chen WY, Gu J, et al. Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics. 2012;2(4):335–345.
   PubMed Web of Science ®Google Scholar
• Kurpisz M, Czepczynski R, Grygielska B, et al. Bone marrow stem cell imaging after intracoronary administration. Int J Cardiol. 2007 Oct 1;121(2):194–195.
   PubMed Web of Science ®Google Scholar
• Pawelczyk E, Arbab AS, Chaudhry A, et al. In vitro model of bromodeoxyuridine or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: implications for cellular therapy. Stem Cells. 2008 May;26(5):1366–1375.
   PubMed Web of Science ®Google Scholar
• Brass SD, Chen NK, Mulkern RV, et al. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging. 2006 Feb;17(1):31–40.
   PubMedGoogle Scholar
• Cheng SH, Yu D, Tsai HM, et al. Dynamic in vivo SPECT imaging of neural stem cells functionalized with radiolabeled nanoparticles for tracking of glioblastoma. J Nucl Med. 2016 Feb;57(2):279–284.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Yang C, Merrill MJ, et al. Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg. 2013 Aug;119(2):427–433.
   PubMed Web of Science ®Google Scholar
• Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. 2009 Oct;9(10):1519–1527.
   PubMed Web of Science ®Google Scholar
• Larsen JM, Martin DR, Byrne ME. Recent advances in delivery through the blood-brain barrier. Curr Top Med Chem. 2014;14(9):1148–1160.
   PubMed Web of Science ®Google Scholar
• Li YH, Feng L, Zhang GX, et al. Intranasal delivery of stem cells as therapy for central nervous system disease. Exp Mol Pathol. 2015 Apr;98(2):145–151.
   PubMed Web of Science ®Google Scholar
• Linares GR, Chiu CT, Scheuing L, et al. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington’s disease. Exp Neurol. 2016;281:81–92.
   PubMed Web of Science ®Google Scholar
• Wei ZZ, Gu X, Ferdinand A, et al. Intranasal delivery of bone marrow mesenchymal stem cells improved neurovascular regeneration and rescued neuropsychiatric deficits after neonatal stroke in rats. Cell Transplant. 2015;24(3):391–402.
   PubMed Web of Science ®Google Scholar
• Liao W, Pham V, Liu L, et al. Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis. Biomaterials. 2016;77:87–97.
   PubMed Web of Science ®Google Scholar